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Inflammatory bowel disease (IBD) in young children can be a clinical manifestation of 
various primary immunodeficiency syndromes. Poor clinical outcome is associated with 
poor quality of life and high morbidity from the complications of prolonged immunosup-
pressive treatment and malabsorption. In 2012, mutations in the lipopolysaccharide-re-
sponsive beige-like anchor (LRBA) gene were identified as the cause of an autoimmunity 
and immunodeficiency syndrome. Since then, several LRBA-deficient patients have been 
reported with a broad spectrum of clinical manifestations without reliable predictive prog-
nostic markers. Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been 
performed in a few severely affected patients with complete or partial response. Herein, 
we present a detailed course of the disease and the transplantation procedure used in 
a LRBA-deficient patient suffering primarily from infantile IBD with immune enteropathy 
since the age of 6  weeks, and progressive autoimmunity with major complications 
following long-term immunosuppressive treatment. At 12 years of age, alloHSCT using 
bone marrow of a fully matched sibling donor—a healthy heterozygous LRBA mutant 
carrier—was performed after conditioning with a reduced-intensity regimen. During the 
6-year follow-up, we observed a complete remission of enteropathy, autoimmunity, and 
skin vitiligo, with complete donor chimerism. The genetic diagnosis of LRBA deficiency 
was made post-alloHSCT by detection of two compound heterozygous mutations, 
using targeted sequencing of DNA samples extracted from peripheral blood before the 
transplantation.
Keywords: infantile IBD, autoimmune cytopenia, lipopolysaccharide-responsive beige-like anchor gene, stem cell 
transplantation, vitiligo
INtRoDUCtIoN
Enteropathy is one of the major clinical symptoms of several primary immunodeficiencies (PIDs) 
(1), such as immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, 
and chronic granulomatous disease (CGD), as well as the IL-10/IL-10-receptor (2), CD25 (3), 
and Stat5b deficiency (4). Recently, several novel PIDs, resulting primarily in autoimmunity and 
FIGURe 1 | Clinical course of the disease and immunosuppressive 
treatments provided to the lipopolysaccharide-responsive beige-like 
anchor-deficient patient. PR, partial remission; NR, non-response. Gray 
shading indicates progressive symptoms.
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immune dysregulation, were added to this group. Examples are 
the disorders caused by the deficiency of the lipopolysaccharide-
responsive beige-like anchor (LRBA) (5, 6), the cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4) (7), and the mucosa 
associated lymphoid tissue lymphoma translocation 1 (8), as well 
as the syndromes caused by gain-of-function mutations of the 
signal transducer and activator of transcription 1 (STAT1) (9) and 
STAT3 (10, 11).
Among these disorders, LRBA and CTLA-4 deficiencies seem 
to have similar symptoms; patients of both develop primarily 
heterogeneous multiorgan autoimmunity. Inflammatory bowel 
disease (IBD) occurs in about 70% of affected patients. Other 
symptoms include hypogammaglobulinemia, autoimmune 
cytopenia, endocrine manifestations, and lymphoproliferation 
(7, 12, 13).
Lipopolysaccharide-responsive beige-like anchor is involved 
in critical cellular processes, such as apoptosis and autophagy, 
and plays a role in immune system regulation (14). There is 
evidence that LRBA influences CTLA-4 homeostasis and, by 
extension, the suppressive capacity of regulatory T-cells (Tregs) 
by preventing CTLA-4 degradation in endocytic lysosomes (15). 
Some authors classify LRBA and CTLA-4 deficiencies as “Treg-
opathies” with an IPEX-like disease phenotype (16). Notably, 
and in contrast to patients with IPEX or LRBA deficiency, 
CTLA-4-deficient patients seem to show a later disease manifes-
tation during their second decade of life. However, the clinical 
manifestations and the severity of the symptoms among affected 
patients remain heterogeneous (12, 13, 17–19). Moreover, these 
disorders lack a clear genotype–phenotype correlation, and cor-
responding prognostic and predictive biomarkers have not yet 
been established.
Severely affected patients do not respond to standard 
immunosuppressive treatment, such as methotrexate, sirolimus, 
azathioprine, cyclosporine A, and steroids (12, 13). For patients 
with IBD as their major symptom, malabsorption and failure to 
thrive are common complications, compromising the outcome 
of the disease and the patient’s quality of life. Frequently, multiple 
immunosuppressive treatments result in infectious and non-
infectious complications, exacerbating the disease.
For some well-defined PIDs, such as the severe combined 
immunodeficiency (SCID) and CGD, there are clear indications 
for early allogeneic hematopoietic stem cell transplantation 
(alloHSCT) or, in some cases, gene therapy. In contrast, there 
are often no clear indications for early alloHSCT in patients 
with novel immune system-dysregulative PIDs, as these exhibit 
heterogeneous disease manifestations and a lack of genotype–
phenotype correlation.
To date, three reports are available on alloHSCT-treated 
severely affected patients from consanguineous families harbor-
ing homozygous LRBA mutations (20–22). Herein, we describe 
the detailed clinical course of the disease in a Caucasian child 
diagnosed with a therapy-refractory infantile IBD with autoim-
munity, caused by two compound heterozygous LRBA muta-
tions. The patient underwent successful alloHSCT at 12  years 
of age with non-myeloablative conditioning. During the 6-year 
follow-up, we observed a stable engraftment and complete donor 
chimerism. Major symptoms of LRBA deficiency, enteropathy, 
and autoimmune cytopenia resolved completely, while partial 
resolution of vitiligo was evident.
MetHoDs
Case Report
The patient, currently 18 years old, first presented chronic diarrhea 
and failure to thrive at the age of 6 weeks. Gastroscopy revealed 
changes suggesting celiac disease. He was started on a gluten-free 
diet, without amelioration of the symptoms. Progressive vitiligo 
appeared at the age of 1 year. At 4.5 years of age, immunosuppres-
sive treatment with cyclosporine A was started, resulting in the 
partial remission of enteropathy (Figure 1). The patient’s IBD was 
progressive. At 12 years of age, gastroscopy including histological 
assessment of gastric biopsies revealed an antiparietal cell-posi-
tive autoimmune gastritis characterized by atrophy, metaplasia, 
and endocrine cell hyperplasia (Figures  2A,B), providing an 
explanation for patient’s vitamin B12 deficiency refractory to 
oral substitution. Colonoscopy showed autoimmune colitis with 
graft versus host-like features with lymphofollicular hyperplasia, 
increased epithelial regeneration, and increased apoptosis with-
out any signs of infectious agents (Figures  2C,D). The patient 
developed aseptic polyarthritis affecting both knees and ankles 
at 5 years, and autoimmune thrombocytopenia at 7 years. At this 
stage, the immunosuppressive treatment included high doses of 
steroids, sirolimus, azathioprine, and multiple courses of rituxi-
mab; this regimen resulted in a short-term partial remission of the 
symptoms. By the age of 12 years, three episodes of autoimmune 
hemolytic anemia had occurred. A combination of rituximab, 
sirolimus, and an escalated dosage of steroid (prednisolone, 
2 mg/kg/day) was required to keep the symptoms under control. 
The patient developed severe secondary Cushing’s syndrome and 
exhibited complete stagnation of growth (Figure 3). By the age 
of 12, a body weight of 23 kg (4 kg below P3), a height of 122 cm 
(14 cm below P3), and a body mass index of 16 were documented 
(Figures 3A–E). Assessment of bone age according to Greulich 
and Pyle revealed a significant developmental delay (5 years) and 
severe osteopenia.
FIGURe 2 | Gastroscopic findings of the patient showing atrophic 
gastritis with visible vessels in the corpus and fundus ventriculi (a), 
shiny mucosa with few villi but without macroscopic lesions in the 
duodenum (B), terminal ileum without visible lymph follicles (C), and 
normal cecum with ileocecal valve (D).
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The patient’s immunological workup at 8  years of age (on 
prednisolone and azathioprine) showed normal levels of 
immunoglobulins (Igs) G, M, A, and E; low levels of tetanus 
vaccine antibodies, and; moderate T-cell lymphocytopenia 
(CD3+: 1,230  cells/μL [non-response (NR): 1,100–5,900/μl]) 
with normal distribution of CD4+ and CD8+ T-cells, naive 
CD4+ (CD4+CD45RA+CD62L+) T-cells, and double-
negative T-cells (CD3+CD4−CD8−TCRα/β and γ/δ). Tregs 
(CD4+CD25+Foxp3+) were reduced [2.5% (NR > 5%)]. T-cell 
proliferation, assessed by phytohemagglutinin (PHA) stimu-
lation of CD4+ and CD8+ T-cells, and the V-beta repertoire 
of CD4+ and CD8+ T-cells were within normal ranges. Also 
the counts of NK cells (CD3−CD56+) and B-cells (CD19+), 
as well as those of the memory and class-switched memory 
B-cells (CD19+CD27+IgD−) were normal. Direct and indirect 
Coombs’ tests were positive with detectable anti-erythrocyte 
antibodies. Endocrine parameters, including thyroid and 
growth hormones, were unremarkable. Antinuclear antibod-
ies as well as antibodies against lactoferrin, carboanhydrase I, 
carboanhydrase II, and parietal cells, were not detectable. High 
levels of the autoimmune enteropathy-related antigen [AIE-75, 
187.4 (NR ratio < 10)] antibodies were detected in plasma using 
radioimmune precipitation assay, indicating an autoimmune 
enteropathy (Table 1).
Genetic Workup
Both written parental consent and approval by the Ethics 
Committee of the University Hospital Frankfurt were obtained. 
Sanger sequencing of genomic DNA extracted from peripheral 
blood was performed to identify SCID-causing mutations in 
the RAG1, RAG2, DCLRE1C, LIG4, and XLF genes. Two het-
erozygous variants with unknown pathogenicity were detected in 
RAG1 and RAG2 (one variant for each gene). No disease-causing 
mutations were found in FOXP3. The clinical manifestation of the 
disease was evaluated as IPEX-like.
LRBa protein Detection by  
Flow Cytometry
Isolated peripheral blood mononuclear cells (PBMCs) were 
stimulated with 10  ng/µl of PHA (cat. L1668, Sigma-Aldrich, 
St. Louis, MO, USA) for 72 h. Intra cellular expression of LRBA 
in unstimulated and stimulated PBMCs was determined by 
flow cytometry. Briefly, 3 ×  105 cells were permeabilized and 
fixed using the BD Cytofix/Cytoperm solution (cat. 554715; BD 
Biosciences, Great Lakes, NJ, USA), stained with rabbit polyclonal 
anti-LRBA antibody (cat. HPA023597; Sigma-Aldrich), followed 
by PE-conjugated F(ab’)2 Donkey anti-Rabbit IgG (cat. 558416; 
BD Biosciences). Cells were analyzed on a FACSCanto II system 
(BD Biosciences). Data analysis was performed using FlowJo v10 
(TreeStar Inc., Ashland, OR, USA). Mean fluorescence intensities 
were calculated and compared with those of non-related healthy 
controls.
LRBA Mutation Detection
The identification of the genetic defect was performed on 
genomic DNA extracted from frozen PBMC samples collected 
4 weeks prior to alloHSCT. Briefly, 225 ng of gDNA was digested 
and hybridized with a HaploPlex biotinylated probe library 
(Agilent Technologies, Santa Clara, CA, USA) in the presence 
of an indexing primer cassette for enrichment. After captur-
ing and ligating the circularized target DNA-probe hybrids on 
streptavidin beads, targeted fragments were amplified by PCR. 
Sample barcodes were introduced during amplification for 
precise tracking. Elution, PCR amplification, and pooling of 
the targeted samples with different indexes were performed to 
prepare for multiplex sequencing on the Illumina MiSeq plat-
form (Illumina, San Diego, CA, USA). On average, 99% of exon 
bases at a depth of at least 38 × were covered. The sequences 
were aligned to the human genome using the Agilent SureCall 
software (Agilent Technologies). LRBA mutations detected by 
next-generation sequencing were validated by Sanger sequenc-
ing. The PCR products were sequenced in both directions and 
analyzed with Sequencer v4.10.1 (Gene Codes Corporation, Ann 
Arbor, MI, USA).
ResULts
transplantation procedure
Severe enteropathy refractory to immunosuppressive therapy 
that necessitated parenteral nutrition, as well as the development 
of autoimmunity by the age of 12 years, justified alloHSCT as an 
experimental curative option, although genetically confirmed 
diagnosis was not available at that stage. Secondary symptoms 
A B
C
D
E
FIGURe 3 | Development of secondary Cushing’s syndrome (a,B), vitiligo (C,D), and complete growth stagnation with post-alloHsCt growth 
acceleration (e).
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following long-term steroid treatment, such as significantly 
reduced numbers of T-, B-, and NK cells, growth stagnation, and 
progressive Cushing’s syndrome, also constituted major indica-
tions for alloHSCT. A clinically healthy 15-year-old sibling 
sharing the patient’s human leukocyte antigen (HLA) served as 
the donor. The patient received unmanipulated bone marrow 
containing 12.9 × 106 CD34+cells/kg and 36.2 × 106 CD3+ cells/
kg following a non-myeloablative conditioning regimen includ-
ing fludarabine (5 × 40 mg/m2), melphalan (2 × 70 mg/m2), and 
thiotepa (2 × 5 mg/kg). Anti-thymocyte globulin (3 × 20 mg/
kg) was used as serotherapy from day −4 to day −1. Graft versus 
host disease (GVHD) prophylaxis consisted of cyclosporine 
A  (from day −1; dose was adjusted to achieve serum trough 
levels of 100–150 ng/ml) and low doses of methotrexate (10 mg/
m2) on days +1 and +3 post-HSCT (Table 2). The conditioning 
regimen was tolerated well without any signs of organ toxicity. 
Two episodes of febrile neutropenia were observed on days −3 
and +10, which were resolved with appropriate anti-infective 
treatments. No virus reactivation or opportunistic infections 
occurred.
engraftment, GVHD, and Chimerism
An uncomplicated engraftment was observed. Leukocyte and 
granulocyte recovery occurred on days +17 and +18, respectively. 
Thrombocyte recovery was observed on day +45 post-HSCT. The 
patient developed intermittent acute GVHD grade I–II, which 
was limited to the skin. No additional treatment was required. 
During the 6-year follow-up, no signs of de novo onset of acute 
or chronic GVHD were observed. The patient has remained 
off immunosuppression since day +70. Stable chimerism was 
observed in T-cells (100% of donor) and whole blood (100% of 
donor) beginning from day +19 onward.
Clinical and Immunological Recovery
With respect to the clinical symptoms associated with the 
underlying disease, enteropathy and multisystemic autoimmun-
ity resolved completely after alloHSCT. No further episodes of 
chronic diarrhea and malabsorption were observed. Autoimmune 
hemolytic anemia or cytopenia were not observed, either. During 
the 6-year follow-up, a partial re-pigmentation of the vitiligo 
taBLe 2 | transplant characteristics.
transplant characteristics
Donor 10/10 MSD
CMV status Positive donor/negative recipient
Blood group O Rh+ (both donor and recipient)
Stem cell source Bone marrow
Cell dose/kg
CD34+ 12.9 × 106
CD3+ 36.2 × 106
Conditioning regimen Non-myeloablative
Fludarabin 5 × 40 mg/m2
Thiotepa 2 × 5 mg/kg
Melphalan 2 × 70 mg/m2
Serotherapy
ATG 3 × 20 mg/kg
Time to engraftment (day)
Neutrophils (ANC > 0.5 × 109/nl) 17
Platelets (>20 × 109/nl) 11
Thrombocytes (> 50/nl) 45
GCSF 5 µg/kg (days 14–20)
Transfusions post-transplant
Red cells (U) 6
Platelets (U) 18
Graft versus host disease (GVHD) prophylaxis Cyclosporine A  
(trough level 100–150 ng/ml)
GVHD
Acute, grade Skin I–II (limited)
Chronic No
Chimerism (whole blood) 100% donor (day +19 onward)
Lansky performance score, last follow-up 100%
Follow-up (months) 72
taBLe 1 | Laboratory workup of the patient with lipopolysaccharide-
responsive beige-like anchor deficiency.
Lab results Normal range patient
WBC 4–11/nl 8.2
Hb 11–15 g/l 7.3*
Thrombocytes 200–400/nl 40#
T-lymphocytes (CD3+) 700–4,200/nl 794*
Granulocytes 1.8–7.1/nl 2.1**
CD4+ T-cells 300–2,000/μl 425*
CD8+ T-cells 300–1,800/μl 313*
Naive CD4+ (CD4+CD45RA+CD62L+) 220–873/μl 254*
DNT (CD3+TCRg/d+CD4−CD8−) <5% 1.7%*
Regulatory T-cells (CD4+CD25+FoxP3+) 5–10% 2.8%*
B-cells (CD19+) 200–1,500/μl 306*
PHA Normal*
V-beta CD4+ and CD8+ Normal*
Switched memory B (CD19+CD27+IgD−) >5% 8%*
Non-switched memory B (CD19+CD27+IgD+) >5% 4%*
NK cells (CD3−CD56+) 60–900/μl 69
IgG 590–1,400 mg/dl 780**
IgM 50–317 mg/dl 60*
IgA 70–250 mg/dl 109**
IgE <100 U/ml 1
Coombs test − ++**
Anti-thrombocyte Ab − ++**
Anti-granulocyte Ab − ++**
TSH 0.5–3.6 mU/l 2.0*
fT4 0.9–1.6 ng/dl 1.2*
IgfBP3 2.3–8.3 µg/ml 3.4**
IGF-1 101–538 ng/ml 151**
Anti-TG Ab <40 IU/ml <40*
Anti-TPO Ab <35 IU/ml <35*
Anti-gliadin Ab <15 U/ml 0.8*
Anti-lactoferrin Ab <10 2.1*
Anti-carboanhydrase I Ab − −*
Anti-carboanhydrase II Ab − −*
ANA − −*
Antiparietal cell Ab − +**
AIE-75 <10 187.4*
*, **, and # indicate values obtained at 8, 9, and 11 years of age, respectively (no 
single age at which all tests had been done was available). − indicates non-detectable; 
+, ++, and +++ indicate weak, medium, and strong signals, respectively. PHA, 
phytohemagglutinin; DNT, double-negative T-cells; V-beta, T-cell receptor V-beta 
repertoire; NK, natural killer cells; TSH, thyroid-stimulating hormone; fT4, free thyroxine; 
IgfBP3, insulin-like growth factor-binding protein 3; IGF-1, insulin-like growth factor-1; 
TG, thyroglobulin; TPO, thyroperoxidase; ANA, antinuclear antibodies; AIE-75, 
autoimmune enteropathy antibody-75. Bold font is used for patient results outside the 
normal range.
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was observed. The cushingoid habitus regressed and the patient 
gained height (Figure 3E). The patient was expected to achieve 
the constitutionally determined height. Following alloHSCT, 
the patient developed age-normal T-, B-, and NK cell counts, as 
well as Ig serum levels. Protective antibody titers to tetanus and 
hepatitis-B vaccines were observed.
post-transplantation establishment  
of the Underlying Diagnosis
We performed targeted sequencing for a screening panel of 
“common variable immune deficiency (CVID) candidate genes” 
(Table  3). The patient harbored two compound heterozygous 
mutations of the LRBA gene: a heterozygous novel frameshift 
mutation (c.3647_3651delCTAA) as well as an already described 
mutation (c.7937T>G: I2646S). The patient’s father was found 
to harbor one heterozygous c.3647_3651delCTAA mutation. 
The patient’s mother was a healthy heterozygous carrier of the 
I2646S mutation. This mutation has been reported to cause LRBA 
deficiency in the homozygous state. The patient’s brother, i.e., the 
healthy stem cell donor, was heterozygous for I2646S. Moreover, 
this heterozygous mutation was the only one found in the post-
HSCT DNA samples of the patient (Figure 4).
Lipopolysaccharide-responsive beige-like anchor protein 
expression was analyzed by flow cytometry in PBMCs from fresh 
samples. The patient’s brother and parents showed normal LRBA 
expression comparable to the post-HSCT LRBA expression in 
the patient and two unrelated healthy controls, confirming that 
the presence of only one heterozygous variant does not affect the 
expression of the LRBA protein (Figure 4). Pre-alloHSCT vital 
cells of this patient were not available; therefore, the LRBA expres-
sion levels before transplantation could not be assessed. However, 
the clinical symptoms of the disease were in line with the diagnosis 
of LRBA deficiency, and the compound heterozygous mutations 
were identified as deleterious. Possible alternative diagnoses, such 
as atypical SCID, CD25 deficiency, IPEX, or CTLA-4-deficiency 
A B
FIGURe 4 | sequencing chromatograms of lipopolysaccharide-responsive beige-like anchor (LRBa) variants from genomic DNa extracted from the 
peripheral blood of the patient 4 weeks before and 1 year after HsCt (frozen DNa samples) as well as from genomic DNa isolated from the patient’s 
parents and brother. Deleted nucleotides are denoted by a box. The missense mutation is indicated by an arrow (a). LRBA expression levels in the patient 
post-alloHSCT, his clinically healthy parents and brother, and two non-related healthy controls. LRBA expression was measured in total peripheral blood 
mononuclear cells before and 3 days after phytohemagglutinin stimulation (B).
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were ruled out based on the results of functional assays and/or 
genetic workup.
DIsCUssIoN
We report the successful treatment of LRBA deficiency-caused 
severe infantile enteropathy by alloHSCT using 10/10 HLA-
matched bone marrow cells of a clinically healthy LRBA-
heterozygous sibling. During a long-term follow-up, we observed 
a complete remission of all LRBA deficiency-related symptoms in 
our patient without transplantation-related complications.
Heritable monogenic PIDs with a predominant autoimmune 
phenotype have overlapping symptoms that lie within the clini-
cal spectrum of IBD. The current classification distinguishes IBD 
subtypes by age of onset: neonatal IBD (develops before the 
first 28 days of life), infantile IBD (before 2 years of age), very 
early-onset IBD (VEOIBD, before 6  years of age), and early-
onset IBD (EOIBD, before 10 years of age) (1). There is evidence 
for a high prevalence of monogenic PIDs among patients with 
infantile IBD, EOIBD, or VEOIBD, which is in contrast to the 
multifactorial pathogenesis of IBD in adults (1, 23). Whereas 
some patients suffer from a combination of the disease-defining 
symptoms, others might initially only present therapy-refractory 
enteropathy, delaying diagnosis and application of disease-
specific treatment. Early diagnosis of the underlying disease is 
important in order to provide optimal treatment, and it may be 
a challenge in such patients. There have been about 50 reported 
cases of patients diagnosed with LRBA deficiency syndrome; they 
present a broad spectrum of clinical manifestations, ranging from 
severe multisystemic immunodysregulative disorder (12, 13, 16, 
18) to isolated endocrine disease lacking a clear genotype–phe-
notype correlation (19). While some of these patients died early 
because of enteropathy and complications of immunosuppres-
sive treatment, others remained stable with or without systemic 
immunosuppression.
Maintaining a distinction between immunity and autoim-
munity requires a complex interaction of activating and inhibit-
ing factors. CTLA-4, mainly localized in intracellular vesicles 
of Tregs, is a key regulator molecule in this cascade. By acting 
as an early negative checkpoint, CTLA-4 exerts a major influ-
ence on maintaining self-tolerance (24). There is evidence that 
LRBA controls CTLA-4 expression by preventing its recycling 
taBLe 3 | List of variants in coding regions detected by using next-generation targeted sequencing on genomic DNa extracted from peripheral blood 
before the alloHsCt.
Gene Ref allele alt allele allele frequency primary effect|function class sIFt score polyphen2 score
LRBa GGttaGtt GGtt 0.5 FRaMe_sHIFt|NM_001199282
RIF1 G A 1.0 NON_SYNONYMOUS_CODING|NM_001177663
RIF1 G A 1.0 NON_SYNONYMOUS_CODING|NM_001177663 1.80E−01 B
RIF1 A T 1.0 NON_SYNONYMOUS_CODING|NM_001177663 4.10E−01 B
RIF1 C G 1.0 NON_SYNONYMOUS_CODING|NM_001177663 1.00E+00 B
CD86 G A 1.0 NON_SYNONYMOUS_CODING|NM_001206925 2.90E−01 B
GATA2 C T 0.5 NON_SYNONYMOUS_CODING|NM_001145661 4.10E−01 B
TFRC C T 0.5 NON_SYNONYMOUS_CODING|NM_001128148 4.00E−02 D
TFRC C T 0.5 NON_SYNONYMOUS_CODING|NM_001128148 6.30E−01 B
LRBA G A 0.5 NON_SYNONYMOUS_CODING|NM_001199282 6.70E−01 B
LRBA C T 0.5 NON_SYNONYMOUS_CODING|NM_001199282 1.80E−01 B
LRBa a C 0.5 NoN_sYNoNYMoUs_CoDING|NM_001199282 0.00e+00 p
TNFSF13 G A 0.5 NON_SYNONYMOUS_CODING|NM_001198624 5.80E−01 B
TNFSF12-TNFSF A G 1.0 NON_SYNONYMOUS_CODING|NM_172089 1.00E+00 B
Bold font is used to highlight the pathogenic LRBA variants.
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in lysosomes, thereby supporting its trans-endocytotic function 
and, as a result, the suppressive capacity of Tregs (15). Some 
LRBA-deficient patients with detectable levels of residual LRBA 
were reported to have increased CTLA-4 levels, suggesting 
a quantitative correlation between CTLA-4 deficiency and 
residual LRBA protein levels in LRBA-deficient patients (15). 
However, other LRBA-deficient patients display Treg counts 
within the normal range (13, 19). Moreover, there have been 
reports of genetically and functionally confirmed CTLA-4-
deficient patients with reduced Treg function who remained 
asymptomatic in the second decade of life (7). There is also 
evidence for marked Treg dysfunction and skewing in favor of 
memory T-cells, intense autoantibody production with marked 
expansion of T follicular helper cells, and contraction of T folli-
cular regulatory cells in LRBA-deficient patients (16). The extent 
of a possible quantitative correlation between Treg dysfunction 
and disease severity in these patients should be evaluated in 
further studies prior to the initiation of immunosuppressive 
treatment. A recent study postulated a possible role of the base 
excision repair enzyme Nei endonuclease VIII-like 3 (NEIL3) 
deficiency as an additional factor contributing to autoimmunity 
in the presence of LRBA deficiency (25).
For severely affected patients, a wide range of immunosup-
pressive treatment has been reported as partially beneficial (3, 
4). Abatacept, a CTLA-4 fusion protein, has been shown to have 
a beneficial effect in some LRBA-deficient patients; however, 
no long-term data on its efficacy and safety are yet available. 
Furthermore, chloroquine, a lysosomal inhibitor drug used 
against malaria, was found to augment CTLA-4 levels in vitro in 
Tregs and activated T-cells of LRBA-deficient patients (15).
However, there is accumulating evidence for early alloHSCT 
being the only curative therapeutic approach for patients suffer-
ing from monogenic PIDs causing severe enteropathy, such as 
IL10/IL10R deficiency (26), the IPEX syndrome (27, 28), and 
CTLA-4 deficiency (29).
There are three reported cases of alloHSCT performed in 
patients from consanguineous families who were retrospectively 
diagnosed with homozygous LRBA mutations; in all cases, 
non-myeloablative conditioning regimens including fludarabin 
in combination with treosulfan, busulfan, or melphalan and 
serotherapy were used (20–22). One patient experienced a com-
plete resolution of the disease symptoms following alloHSCT, 
while the second patient displayed various complications, ade-
noviremia and HHV-6 infection with pancytopenia, suspected 
graft failure, and alloimmune liver disease. Stable engraftment 
in this patient was ultimately achieved after the application 
of a stem cell boost and growth factor on day +60. Immune 
thrombocytopenia (ITP) and vitiligo relapsed in this patient 
four years post-HSCT after the termination of the immunosup-
pressive treatment, necessitating intermittent ITP-treatment 
with romiplostim (21). Post-HSCT ITP was also observed in 
another patient with the same underlying LRBA mutation as 
the second patient (c.7162delA). Both patients received stem 
cells from an HLA-identical heterozygous family donor and 
achieved full donor chimerism without obvious signs of acute or 
chronic GVHD. The authors concluded that grafts from donors 
harboring heterozygous LRBA mutations might induce subclini-
cal autoimmunity; thus, they may not represent the best donor 
choice. Interestingly, a full remission of thrombocytopenia was 
observed in both patients, following romiplostim treatment in 
one patient, and spontaneously in the other patient. During the 
long-term follow-up period, no further LRBA-associated disease 
manifestations were observed in either patient. Our results are 
in keeping with these previous studies and confirm that enter-
opathy and autoimmunity in LRBA deficiency can be corrected 
completely by alloHSCT. However, it remains unclear whether 
LRBA-heterozygosity in clinically healthy stem cell donors has 
any effect on the status of autoimmunity as a residual disease 
in transplanted patients. In our case, post-HSCT-heterozygosity 
did not induce any disease-related symptoms.
Young age lowers the risk of transplantation-related mortality 
(TRM) because it is associated with lower comorbidity and less 
frequent end-organ damage caused by the underlying disease. 
Careful selection of the pre-transplantation conditioning regimen 
can significantly reduce early TRM in certain PIDs and increase 
the probability of stable engraftment in others (7).
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Due to the lacking genotype–phenotype correlation in LRBA-
deficient patients, further data are necessary to establish predic-
tive and prognostic biomarkers that would allow the reliable 
identification of candidates for early alloHSCT. Further studies 
on transplantation in LRBA deficiency are necessary to evaluate 
the optimal conditioning regimen and determine the necessary 
level of chimerism for disease remission.
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